2024
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsEGFR declineGlomerular filtration rateEjection fractionHeart failurePrespecified analysisFiltration rateMonths 1Estimated glomerular filtration rateDapagliflozin-treated patientsKidney composite outcomePrimary cardiovascular outcomeHeart Failure TrialChronic kidney diseaseCotransporter 2 inhibitorsInternational multicenter studyLives of patientsBaseline eGFRKidney eventsKidney outcomesCardiovascular outcomesComposite outcomePrognostic factorsFailure TrialMulticenter study
2023
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.Peer-Reviewed Original ResearchConceptsBaseline kidney functionKidney composite outcomeEffect of dapagliflozinEjection fractionHeart failureKidney outcomesComposite outcomePrimary outcomeKidney functionKidney diseaseSodium-glucose cotransporter 2 inhibitorsBaseline eGFR categoryBaseline kidney diseaseBenefit of dapagliflozinComposite kidney outcomeHeart Failure TrialReduced ejection fractionCotransporter 2 inhibitorsHeart failure eventsGlomerular filtration rateOverall incidence rateOverall event rateLives of patientsTreatment effectsEGFR categories
2022
Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
Yeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.833. DOI: 10.1093/eurheartj/ehac544.833.Peer-Reviewed Original ResearchBaseline ET-1 concentrationET-1 concentrationsBaseline ET-1Benefit of dapagliflozinSerum ET-1Kidney functionEndothelin-1Tertile 3NT-proBNPPrimary outcomeCirculating Endothelin-1DAPA-HF trialEfficacy of dapagliflozinET-1 measurementsHeart Failure TrialReduced ejection fractionWorse functional statusET-1 levelsHeart failure outcomesHeart failure severityHigh-sensitivity troponinDAPA-HFCardiovascular deathEGFR slopeLower eGFR
2020
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF
Kristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. European Heart Journal 2020, 41: ehaa946.0939. DOI: 10.1093/ehjci/ehaa946.0939.Peer-Reviewed Original ResearchMineralocorticoid receptor antagonistsRisk of hyperkalaemiaReduced ejection fractionSevere hyperkalaemiaMild hyperkalaemiaDAPA-HFHazard ratioEjection fractionHeart failureMRA useSodium-glucose cotransporter 2 inhibitor dapagliflozinDAPA-HF studyHeart Failure TrialCox regression analysisLife-saving therapyInhibitor dapagliflozinFailure TrialAdverse outcomesReceptor antagonistHyperkalaemiaPatientsDapagliflozinTreatment assignmentHFrEFPlacebo